

Table S5. Univariate analysis of prognostic factors for acute myeloid leukemia-free survival.

<i>Clinical variable</i>	5-y AFS	<i>P</i> -value			
Sex					
Female	73.0%	0.057			
Male	81.2%				
Age, year					
<50	80.1%	0.210			
≥50	72.3%				
IPSS-R					
Lower-risk	84.4%	0.001			
Higher-risk	68.6%				
<i>Genetic aberrations</i>	Somatic mutations only		Somatic mutations + CNAs		
	5-y AFS (WT vs. MT)	<i>P</i> -value	5-y AFS (WT vs. MT)	<i>P</i> -value	
<i>NRAS</i>	78.0% vs. 41.7%	0.002	78.2% vs. 42.9%	<0.001	
<i>DNMT3A</i>	79.3% vs. 45.8%	<0.001	79.3% vs. 45.8%	<0.001	
<i>SF3B1</i>	76.1% vs. 76.9%	0.791	76.1% vs. 76.9%	0.791	
<i>IDH1</i>	75.4% vs. NA	0.127	75.4% vs. NA	0.127	
<i>TET2</i>	77.5% vs. 69.6%	0.213	76.8% vs. 73.7%	0.564	
<i>NPM1</i>	76.4% vs. 50.0%	0.644	76.7% vs. 33.3%	0.254	
<i>LAMB4</i>	77.6% vs. 56.1%	0.034	78.4% vs. 48.3%	0.012	
<i>EZH2</i>	76.2% vs. 75.0%	0.929	77.2% vs. 67.0%	0.587	
<i>JAK2</i>	76.5% vs. 66.7%	0.516	76.2% vs. 77.1%	0.898	
<i>CBL</i>	76.8% vs. 60.6%	0.232	77.6% vs. 54.7%	0.007	
<i>ETV6</i>	75.5% vs. 82.2%	0.255	76.1% vs. 75.4%	0.779	
<i>KRAS</i>	76.6% vs. 67.7%	0.466	77.3% vs. 72.0%	0.658	
<i>FLT3</i>	76.3% vs. 66.7%	0.479	76.3% vs. 66.7%	0.479	
<i>IDH2</i>	75.9% vs. NA	0.336	76.3% vs. 73.3%	0.866	
<i>PRPF8</i>	75.7% vs. 77.8%	0.644	75.9% vs. 70.7%	0.926	
<i>TP53</i>	77.1% vs. 68.2%	0.492	77.1% vs. 68.2%	0.492	
<i>NF1</i>	74.5% vs. 89.5%	0.170	74.5% vs. 89.5%	0.170	
<i>SRSF2</i>	76.1% vs. 83.3%	0.649	76.1% vs. 83.3%	0.649	
<i>SETBP1</i>	75.7% vs. 78.9%	0.881	76.0% vs. 76.5%	0.858	
<i>DNMT1</i>	76.7% vs. 37.5%	0.090	77.2% vs. 35.7%	0.012	
<i>ASXL1</i>	75.3% vs. 81.8%	0.437	75.7% vs. 78.5%	0.698	
<i>RUNX1</i>	75.6% vs. 81.2%	0.779	76.2% vs. 75.8%	0.694	
<i>U2AF1</i>	75.6% vs. 78.1%	0.682	76.1% vs. 76.3%	0.964	
<i>ZRSR2</i>	75.5% vs. 100%	0.503	75.8% vs. 87.5%	0.973	
<i>ATRX</i>	75.5% vs. NA	0.162	75.5% vs. NA	0.162	
<i>STAG2</i>	76.0% vs. 78.8%	0.724	76.0% vs. 78.8%	0.724	
<i>MMP8</i>	75.9% vs. NA	0.356	75.9% vs. NA	0.356	
<i>ARID2</i>	76.3% vs. 68.6%	0.617	76.3% vs. 68.6%	0.617	
CK/TP53					
CK-/WT	77.6%	0.033	77.6%	0.033	
CK-/MT	92.3%				
CK+/WT	71.9%				
CK+/MT	43.3%				

5-y AFS, acute myeloid leukemia-free survival at 5 years; IPSS-R, Revised International Prognostic Scoring System (Lower-risk if score ≤ 3.5 , Higher-risk if score > 3.5); CNAs, copy number alterations; WT, wild type; MT, mutant type; NA, not assessable; CK, complex karyotype (three or more chromosomal abnormalities)